Have we reached proton beam therapy dosimetric limitations? – A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer

Authors

  • Xuanfeng Ding Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA
  • Xiaoqiang Li Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA
  • An Qin Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA
  • Jun Zhou Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA
  • Di Yan Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA
  • Craig Stevens Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA
  • Daniel Krauss Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA
  • Peyman Kabolizadeh Department of Radiation Oncology, Beaumont Health, Royal Oak, MI, USA

DOI:

https://doi.org/10.1080/0284186X.2017.1358463

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2018-03-04

How to Cite

Ding, X., Li, X., Qin, A., Zhou, J., Yan, D., Stevens, C., … Kabolizadeh, P. (2018). Have we reached proton beam therapy dosimetric limitations? – A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncologica, 57(3), 435–437. https://doi.org/10.1080/0284186X.2017.1358463

Issue

Vol. 57 No. 3 (2018): Acta Oncologica

Section

Articles